BioCentury | Dec 2, 2020
Finance

Data Byte: IPO queue picks up post-election

...in a NASDAQ IPO after withdrawing its planned listing in July.On the flipside, immuno-oncology company Compass...
BioCentury | Nov 17, 2020
Regulation

FDA to post data on COVID-19 therapeutic, vaccine EUAs

...on Medical Product Access, Safety and Stewardship (COMPASS). Steve...
BioCentury | Sep 19, 2020
Finance

Athira, Compass IPOs help quartet push biopharmas’ 2020 NASDAQ haul above $9B

...Friday’s session, neurodegeneration play Athira gave back most of its early gains, while depression company Compass...
...in a series B round announced in June (see “Recovering Neuronal Health”).Demand was high for Compass...
...$14-$16.During Friday’s session, Compass gained $12 (71%) to $29, lifting its market cap above $1 billion.Compass’...
BioCentury | Aug 29, 2020
Finance

Aug. 28 Quick Takes: Synthego raises $100M D round, plus Clene, Aetion, Antengene, Athira, Compass

...ATH-1017 in Alzheimer’s disease patients (see “Athira Seeks to Recover Neuronal Health”).Compass seeking U.S. debutU.K.-based Compass...
...high-purity polymorphic crystalline formulation of psilocybin, for treatment-resistant depression. BC Staff Synthego Corp. Clene Nanomedicine Inc. Antengene Corp. Athira Pharma Inc. Compass...
BioCentury | Aug 6, 2020
Politics, Policy & Law

BIO challenging its members to walk the talk on social justice

Outrage over the killing of George Floyd prompted biopharma leaders and companies to look up from their work developing molecules to consider their companies’ roles in advancing social justice. Now BIO is challenging its members...
BioCentury | Jun 25, 2020
Deals

June 24 Quick Takes: CSL pays $450M for uniQure’s hemophilia gene therapy; plus Merck-Yumanity, Editas, Compass-Olivia, Century-Empirica, Tetraphase-La Jolla

...shares fell $3.61 (11%) to $30.73 Wednesday. After merger, Compass raises $60M Antibody therapeutics company Compass...
...raises $60M Antibody therapeutics company Compass completed a reverse merger with Olivia Ventures Inc., becoming Compass...
...S. Eaton, Staff Writer Tetraphase Pharmaceuticals Inc. La Jolla Pharmaceutical Co. Melinta Therapeutics Inc. AcelRx Pharmaceuticals Inc. Century Therapeutics LLC Empirica Therapeutics Compass...
BioCentury | Jun 19, 2020
Politics, Policy & Law

Juneteenth and our path forward: Letter from BioCentury’s Co-Founders

Editor’s Note: BioCentury’s co-founders, Chairman Karen Bernstein, Ph.D., and President & CEO David Flores, have written to the company’s employees about BioCentury’s response to racism and racial inequities in healthcare. It is published in its...
BioCentury | Jun 6, 2020
Politics, Policy & Law

Beyond molecules and microbes: biopharma's responsibility to racial justice in and outside its own walls

The killing of George Floyd has made it clear that life sciences leaders cannot focus exclusively on molecules or microbes, that their missions include helping to heal social as well as physical pathologies. The uncomfortable...
BioCentury | Apr 28, 2020
Finance

April 27 Quick Takes: Avalyn raises $35M for fibrosis therapies, plus Actym, LifeSprout, HebeCell, Compass, Immunomic

...Bridge Venture Partners and Polaris Venture Partners. Compass completes $80M B round Mental health company Compass...
...Camden Partners Nexus, Perceptive Advisors, Skyviews Life Science and Soleus Capital. The financing will enable Compass...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

...all of the bispecifics discussed are designed to bind T cells. A preclinical study from Compass...
...others each bind two coagulation factors to treat hemophilia. The others include an antibody from Compass...
Items per page:
1 - 10 of 91
BioCentury | Dec 2, 2020
Finance

Data Byte: IPO queue picks up post-election

...in a NASDAQ IPO after withdrawing its planned listing in July.On the flipside, immuno-oncology company Compass...
BioCentury | Nov 17, 2020
Regulation

FDA to post data on COVID-19 therapeutic, vaccine EUAs

...on Medical Product Access, Safety and Stewardship (COMPASS). Steve...
BioCentury | Sep 19, 2020
Finance

Athira, Compass IPOs help quartet push biopharmas’ 2020 NASDAQ haul above $9B

...Friday’s session, neurodegeneration play Athira gave back most of its early gains, while depression company Compass...
...in a series B round announced in June (see “Recovering Neuronal Health”).Demand was high for Compass...
...$14-$16.During Friday’s session, Compass gained $12 (71%) to $29, lifting its market cap above $1 billion.Compass’...
BioCentury | Aug 29, 2020
Finance

Aug. 28 Quick Takes: Synthego raises $100M D round, plus Clene, Aetion, Antengene, Athira, Compass

...ATH-1017 in Alzheimer’s disease patients (see “Athira Seeks to Recover Neuronal Health”).Compass seeking U.S. debutU.K.-based Compass...
...high-purity polymorphic crystalline formulation of psilocybin, for treatment-resistant depression. BC Staff Synthego Corp. Clene Nanomedicine Inc. Antengene Corp. Athira Pharma Inc. Compass...
BioCentury | Aug 6, 2020
Politics, Policy & Law

BIO challenging its members to walk the talk on social justice

Outrage over the killing of George Floyd prompted biopharma leaders and companies to look up from their work developing molecules to consider their companies’ roles in advancing social justice. Now BIO is challenging its members...
BioCentury | Jun 25, 2020
Deals

June 24 Quick Takes: CSL pays $450M for uniQure’s hemophilia gene therapy; plus Merck-Yumanity, Editas, Compass-Olivia, Century-Empirica, Tetraphase-La Jolla

...shares fell $3.61 (11%) to $30.73 Wednesday. After merger, Compass raises $60M Antibody therapeutics company Compass...
...raises $60M Antibody therapeutics company Compass completed a reverse merger with Olivia Ventures Inc., becoming Compass...
...S. Eaton, Staff Writer Tetraphase Pharmaceuticals Inc. La Jolla Pharmaceutical Co. Melinta Therapeutics Inc. AcelRx Pharmaceuticals Inc. Century Therapeutics LLC Empirica Therapeutics Compass...
BioCentury | Jun 19, 2020
Politics, Policy & Law

Juneteenth and our path forward: Letter from BioCentury’s Co-Founders

Editor’s Note: BioCentury’s co-founders, Chairman Karen Bernstein, Ph.D., and President & CEO David Flores, have written to the company’s employees about BioCentury’s response to racism and racial inequities in healthcare. It is published in its...
BioCentury | Jun 6, 2020
Politics, Policy & Law

Beyond molecules and microbes: biopharma's responsibility to racial justice in and outside its own walls

The killing of George Floyd has made it clear that life sciences leaders cannot focus exclusively on molecules or microbes, that their missions include helping to heal social as well as physical pathologies. The uncomfortable...
BioCentury | Apr 28, 2020
Finance

April 27 Quick Takes: Avalyn raises $35M for fibrosis therapies, plus Actym, LifeSprout, HebeCell, Compass, Immunomic

...Bridge Venture Partners and Polaris Venture Partners. Compass completes $80M B round Mental health company Compass...
...Camden Partners Nexus, Perceptive Advisors, Skyviews Life Science and Soleus Capital. The financing will enable Compass...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

...all of the bispecifics discussed are designed to bind T cells. A preclinical study from Compass...
...others each bind two coagulation factors to treat hemophilia. The others include an antibody from Compass...
Items per page:
1 - 10 of 91